Mobile

CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CAN...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002602-20

CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER. Studio clinico e traslazionale di fase II con Doxorubicina Liposomiale (Myocet) più Docetaxel, Trastuzumab e Metformina come terapia sistemica primaria per il cancro della mammella operabile e localmente avanzato Her-2 positivo

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the pathologic complete response rate (pCR). Valutare il tasso di risposta patologica completa (pCR)

Critère d'inclusion

  • OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER,Pazienti con tumore alla mammella HER2-positivo, operabile e localmente avanzato

Liens